JP2012520059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520059A5 JP2012520059A5 JP2011551304A JP2011551304A JP2012520059A5 JP 2012520059 A5 JP2012520059 A5 JP 2012520059A5 JP 2011551304 A JP2011551304 A JP 2011551304A JP 2011551304 A JP2011551304 A JP 2011551304A JP 2012520059 A5 JP2012520059 A5 JP 2012520059A5
- Authority
- JP
- Japan
- Prior art keywords
- functional protein
- binding partner
- protein
- item
- peptide mask
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 111
- 108090000623 proteins and genes Proteins 0.000 claims description 111
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 29
- 239000000758 substrate Substances 0.000 claims description 26
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 229940088598 enzyme Drugs 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 22
- 102000014150 Interferons Human genes 0.000 claims description 19
- 108010050904 Interferons Proteins 0.000 claims description 19
- 108010070047 Notch Receptors Proteins 0.000 claims description 16
- 102000005650 Notch Receptors Human genes 0.000 claims description 16
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 108010047761 Interferon-alpha Proteins 0.000 claims description 9
- 102000006992 Interferon-alpha Human genes 0.000 claims description 9
- 108010091175 Matriptase Proteins 0.000 claims description 9
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 9
- 238000010494 dissociation reaction Methods 0.000 claims description 8
- 230000005593 dissociations Effects 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108091035707 Consensus sequence Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 229940012957 plasmin Drugs 0.000 claims description 5
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims description 4
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- 101000994439 Danio rerio Protein jagged-1a Proteins 0.000 claims description 2
- 102100036462 Delta-like protein 1 Human genes 0.000 claims description 2
- 102100036466 Delta-like protein 3 Human genes 0.000 claims description 2
- 102100033553 Delta-like protein 4 Human genes 0.000 claims description 2
- 108010088842 Fibrinolysin Proteins 0.000 claims description 2
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 claims description 2
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims description 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims description 2
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 claims description 2
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 claims description 2
- 101000599613 Homo sapiens Interferon lambda receptor 1 Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000002227 Interferon Type I Human genes 0.000 claims description 2
- 108010014726 Interferon Type I Proteins 0.000 claims description 2
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 claims description 2
- 102100026720 Interferon beta Human genes 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims description 2
- 102100037971 Interferon lambda receptor 1 Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 108010072610 N-acetyl-gamma-glutamyl-phosphate reductase Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100032702 Protein jagged-1 Human genes 0.000 claims description 2
- 102100032733 Protein jagged-2 Human genes 0.000 claims description 2
- 101710170213 Protein jagged-2 Proteins 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 150000001576 beta-amino acids Chemical class 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229940127276 delta-like ligand 3 Drugs 0.000 claims description 2
- 102000034238 globular proteins Human genes 0.000 claims description 2
- 108091005896 globular proteins Proteins 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 108010018844 interferon type III Proteins 0.000 claims description 2
- 108020001756 ligand binding domains Proteins 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 29
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 108010010648 interferon alfacon-1 Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 51
- 238000012216 screening Methods 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- -1 IFN-ω Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15473009P | 2009-02-23 | 2009-02-23 | |
| US61/154,730 | 2009-02-23 | ||
| PCT/US2010/025121 WO2010096838A2 (en) | 2009-02-23 | 2010-02-23 | Proproteins and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015146309A Division JP2015193653A (ja) | 2009-02-23 | 2015-07-24 | プロタンパク質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520059A JP2012520059A (ja) | 2012-09-06 |
| JP2012520059A5 true JP2012520059A5 (cg-RX-API-DMAC7.html) | 2012-12-06 |
| JP5861223B2 JP5861223B2 (ja) | 2016-02-16 |
Family
ID=42634501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011551304A Active JP5861223B2 (ja) | 2009-02-23 | 2010-02-23 | プロタンパク質およびその使用方法 |
| JP2015146309A Pending JP2015193653A (ja) | 2009-02-23 | 2015-07-24 | プロタンパク質およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015146309A Pending JP2015193653A (ja) | 2009-02-23 | 2015-07-24 | プロタンパク質およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US8399219B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2398494A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5861223B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102481341B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2010215761B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1011384A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2753294A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2011138951A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010096838A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| WO2010004273A1 (en) | 2008-07-07 | 2010-01-14 | Oxford Nanopore Technologies Limited | Base-detecting pore |
| US20110229877A1 (en) | 2008-07-07 | 2011-09-22 | Oxford Nanopore Technologies Limited | Enzyme-pore constructs |
| GB0820927D0 (en) | 2008-11-14 | 2008-12-24 | Isis Innovation | Method |
| CA2749339A1 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| CN102482330A (zh) * | 2009-01-30 | 2012-05-30 | 牛津纳米孔技术有限公司 | 酶突变体 |
| KR101797773B1 (ko) | 2009-01-30 | 2017-11-15 | 옥스포드 나노포어 테크놀로지즈 리미티드 | 막횡단 시퀀싱에서 핵산 구축물용 어댑터 |
| CN102481341B (zh) | 2009-02-23 | 2017-05-17 | 希托马克斯医疗有限公司 | 蛋白原及其使用方法 |
| GB0905140D0 (en) | 2009-03-25 | 2009-05-06 | Isis Innovation | Method |
| AU2012215135B9 (en) | 2011-02-11 | 2017-03-09 | Oxford Nanopore Technologies Limited | Mutant pores |
| CA2843136C (en) | 2011-07-25 | 2020-12-29 | Oxford Nanopore Technologies Limited | Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores |
| EP2768977B1 (en) | 2011-10-21 | 2015-09-23 | Oxford Nanopore Technologies Limited | Method of characterizing a target polynucleotide using a pore and a hel308 helicase |
| EP2798083B1 (en) | 2011-12-29 | 2017-08-09 | Oxford Nanopore Technologies Limited | Method for characterising a polynucelotide by using a xpd helicase |
| WO2013098562A2 (en) | 2011-12-29 | 2013-07-04 | Oxford Nanopore Technologies Limited | Enzyme method |
| KR102083695B1 (ko) | 2012-04-10 | 2020-03-02 | 옥스포드 나노포어 테크놀로지즈 리미티드 | 돌연변이체 리세닌 기공 |
| US11155860B2 (en) | 2012-07-19 | 2021-10-26 | Oxford Nanopore Technologies Ltd. | SSB method |
| EP2875128B8 (en) | 2012-07-19 | 2020-06-24 | Oxford Nanopore Technologies Limited | Modified helicases |
| JP6429773B2 (ja) | 2012-07-19 | 2018-11-28 | オックスフォード ナノポール テクノロジーズ リミテッド | 酵素構築物 |
| US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| EP2895859B1 (en) | 2012-09-12 | 2017-05-17 | The University of Queensland | Protease-based biosensor molecule |
| GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
| SG11201507138RA (en) | 2013-03-08 | 2015-10-29 | Oxford Nanopore Tech Ltd | Enzyme stalling method |
| GB201313477D0 (en) | 2013-07-29 | 2013-09-11 | Univ Leuven Kath | Nanopore biosensors for detection of proteins and nucleic acids |
| KR102182485B1 (ko) * | 2013-05-28 | 2020-11-25 | 카오슝 메디칼 유니버시티 | 단백질 약물의 불활성화를 위한 항체 로커 |
| US20140364368A1 (en) * | 2013-06-06 | 2014-12-11 | Massachusetts Institute Of Technology | Stimulus responsive nanocomplexes and methods of use thereof |
| EP3024851B1 (en) | 2013-07-25 | 2018-05-09 | CytomX Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| AU2014321138A1 (en) | 2013-09-12 | 2016-04-28 | The University Of Queensland | Bimolecular protease-based biosensor |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| GB201406151D0 (en) | 2014-04-04 | 2014-05-21 | Oxford Nanopore Tech Ltd | Method |
| JP6677640B2 (ja) | 2013-10-18 | 2020-04-08 | オックスフォード ナノポール テクノロジーズ リミテッド | 修飾酵素 |
| JP6835586B2 (ja) | 2014-01-31 | 2021-02-24 | シトムクス セラピューティクス，インコーポレイティド | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| US20170165334A1 (en) * | 2015-12-11 | 2017-06-15 | Tianxin Wang | Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification |
| PL3536776T3 (pl) | 2014-04-29 | 2024-03-25 | Novartis Ag | Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania |
| GB201417712D0 (en) | 2014-10-07 | 2014-11-19 | Oxford Nanopore Tech Ltd | Method |
| US10443097B2 (en) | 2014-05-02 | 2019-10-15 | Oxford Nanopore Technologies Ltd. | Method of improving the movement of a target polynucleotide with respect to a transmembrane pore |
| CN106459960A (zh) | 2014-05-13 | 2017-02-22 | 生物蛋白有限公司 | 条件活性生物蛋白 |
| WO2016004383A1 (en) | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| US10669337B2 (en) | 2014-07-25 | 2020-06-02 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
| CN117164683A (zh) | 2014-09-01 | 2023-12-05 | 弗拉芒区生物技术研究所 | 突变csgg孔 |
| EP3204511B1 (en) | 2014-10-07 | 2021-07-28 | Oxford Nanopore Technologies Limited | Mutant pores |
| GB201418159D0 (en) | 2014-10-14 | 2014-11-26 | Oxford Nanopore Tech Ltd | Method |
| EP3244907B1 (en) | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| HK1252158A1 (zh) | 2015-05-01 | 2019-05-17 | Genentech, Inc. | 掩蔽抗cd3抗体和使用方法 |
| JP6857875B2 (ja) * | 2015-05-19 | 2021-04-14 | 国立大学法人 熊本大学 | 新規な細胞膜透過性ペプチド |
| JP2018526972A (ja) | 2015-06-16 | 2018-09-20 | ジェネンテック， インコーポレイテッド | 抗ｃｄ３抗体及び使用方法 |
| BR102016018074A2 (pt) | 2015-08-07 | 2021-11-16 | ALX Oncology Inc. | Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica |
| RS62151B1 (sr) | 2015-08-07 | 2021-08-31 | Alx Oncology Inc | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu |
| US10758886B2 (en) * | 2015-09-14 | 2020-09-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Conditioned surfaces for in situ molecular array synthesis |
| BR112018008390A2 (pt) | 2015-10-30 | 2018-11-27 | Aleta Biotherapeutics Inc | composições e métodos para transdução tumoral |
| MA43135A (fr) | 2015-10-30 | 2018-09-05 | Aleta Biotherapeutics Inc | Compositions et méthodes pour le du traitement du cancer |
| US20210299265A1 (en) | 2016-02-05 | 2021-09-30 | Immunogen, Inc. | Efficient process for preparing cell-binding agent-cytotoxic agent conjugates |
| ES2947230T3 (es) * | 2016-03-22 | 2023-08-03 | Hoffmann La Roche | Moléculas biespecíficas para linfocitos T activadas por proteasa |
| GB201609220D0 (en) | 2016-05-25 | 2016-07-06 | Oxford Nanopore Tech Ltd | Method |
| WO2017203268A1 (en) | 2016-05-25 | 2017-11-30 | Oxford Nanopore Technologies Limited | Method |
| TW202515920A (zh) | 2017-04-11 | 2025-04-16 | 美商因荷布瑞克斯生物科學公司 | 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法 |
| CA3067539A1 (en) * | 2017-06-20 | 2018-12-27 | The Board Of Regents Of The University Of Texas System | Interferon prodrug for the treatment of cancer |
| CN111278461A (zh) | 2017-08-16 | 2020-06-12 | 百时美施贵宝公司 | 可前药化抗体、其前药以及使用和制备方法 |
| EP3694885A1 (en) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| GB201807793D0 (en) | 2018-05-14 | 2018-06-27 | Oxford Nanopore Tech Ltd | Method |
| KR20210038548A (ko) | 2018-06-22 | 2021-04-07 | 큐진 인크. | 사이토카인-기반 생체활성 약물 및 이의 사용 방법 |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| KR20250154552A (ko) | 2018-09-27 | 2025-10-28 | 실리오 디벨럽먼트, 인크. | 마스킹된 사이토카인 폴리펩타이드 |
| TW202028246A (zh) | 2018-10-11 | 2020-08-01 | 美商英伊布里克斯公司 | B7h3單域抗體及其治療性組合物 |
| TW202028245A (zh) | 2018-10-11 | 2020-08-01 | 美商英伊布里克斯公司 | Dll3單域抗體及其治療性組合物 |
| JP7453219B2 (ja) | 2018-10-11 | 2024-03-19 | インヒブリックス， インコーポレイテッド | Ｐｄ－１単一ドメイン抗体およびその治療用組成物 |
| TW202506736A (zh) | 2018-10-11 | 2025-02-16 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
| EP3890764A2 (en) | 2018-12-06 | 2021-10-13 | CytomX Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| AU2019395266A1 (en) * | 2018-12-14 | 2021-06-17 | Proviva Therapeutics (Hong Kong) Limited | IL-15 compositions and methods of use thereof |
| US11136353B2 (en) * | 2019-04-15 | 2021-10-05 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof |
| CA3137512A1 (en) | 2019-05-14 | 2020-11-19 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
| EP3976099A1 (en) | 2019-05-31 | 2022-04-06 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| WO2021055568A1 (en) * | 2019-09-19 | 2021-03-25 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
| MX2022004873A (es) | 2019-10-23 | 2022-05-13 | Cue Biopharma Inc | Polipeptidos de tgf-?. |
| KR20220101147A (ko) | 2019-11-14 | 2022-07-19 | 웨어울프 세라퓨틱스, 인크. | 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법 |
| MX2022009306A (es) | 2020-01-29 | 2022-09-26 | Inhibrx Inc | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. |
| US20210252142A1 (en) * | 2020-02-06 | 2021-08-19 | Aetio Biotherapy, Inc. | Compositions and methods for treating viral infections |
| MX2022011780A (es) | 2020-04-09 | 2022-11-10 | Cytomx Therapeutics Inc | Composiciones que contienen anticuerpos activables. |
| CN115667523A (zh) | 2020-04-10 | 2023-01-31 | 西托姆克斯治疗公司 | 可活化细胞因子构建体和相关组合物以及方法 |
| JP2023550626A (ja) * | 2020-11-23 | 2023-12-04 | キュー バイオファーマ，インコーポレーテッド | ＴＧＦ－βポリペプチド |
| KR20230113581A (ko) | 2020-11-25 | 2023-07-31 | 실리오 디벨럽먼트, 인크. | 종양 특이적 절단성 링커 |
| AU2022237504A1 (en) * | 2021-03-16 | 2023-10-05 | Cytomx Therapeutics, Inc. | Masked activatable cytokine constructs and related compositions and methods |
| IL308400A (en) | 2021-05-13 | 2024-01-01 | Alx Oncology Inc | Combined therapies for cancer treatment |
| CA3221878A1 (en) * | 2021-06-18 | 2022-12-22 | David Stover | Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof |
| JP2024531338A (ja) * | 2021-08-18 | 2024-08-29 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能インターフェロンポリペプチド及びその使用方法 |
| JP2024538706A (ja) | 2021-10-08 | 2024-10-23 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能サイトカイン構成体及び併用方法 |
| IL311971A (en) | 2021-10-08 | 2024-06-01 | Cytomx Therapeutics Inc | Activatable cytokine constructs and related compositions and methods |
| WO2023064791A1 (en) | 2021-10-13 | 2023-04-20 | Cytomx Therapeutics, Inc. | Trimeric activatable cytokine constructs and related compositions and methods |
| EP4499685A1 (en) | 2022-03-25 | 2025-02-05 | CytomX Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| US20250215110A1 (en) | 2022-04-01 | 2025-07-03 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| WO2023192606A2 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| EP4565690A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| TW202424183A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割受質及其使用方法 |
| TW202423953A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| AR130076A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| TW202426637A (zh) | 2022-08-01 | 2024-07-01 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割受質及其使用方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| CN120958015A (zh) | 2023-04-12 | 2025-11-14 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2025007062A1 (en) * | 2023-06-30 | 2025-01-02 | The Regents Of The University Of California | Pro-polypeptides and methods of using and designing the same |
| TW202517789A (zh) * | 2023-07-04 | 2025-05-01 | 香港商禮邦醫藥（香港）有限公司 | Ｋｌｋ１融合蛋白質的製備方法 |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| CN116930512B (zh) * | 2023-09-19 | 2024-01-05 | 细胞生态海河实验室 | 一种用于脑卒中再发风险分析的生物标志物及其应用 |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5686121A (en) | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5306731A (en) | 1985-06-14 | 1994-04-26 | Massachusetts Eye And Ear Infirmary | Method and products for treating the eye |
| US5849478A (en) | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4952394A (en) | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US5144012A (en) | 1988-08-08 | 1992-09-01 | Eli Lilly And Company | Cytotoxic drug conjugates |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5010176A (en) | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
| DE68925366T2 (de) | 1988-11-18 | 1996-10-31 | Univ California | Konjugierte polypeptide und verfahren zur herstellung und verwendung |
| US5162218A (en) | 1988-11-18 | 1992-11-10 | The Regents Of The University Of California | Conjugated polypeptides and methods for their preparation |
| KR0162259B1 (ko) | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| US5272253A (en) | 1991-07-01 | 1993-12-21 | Eli Lilly And Company | Cluster conjugates of drugs with antibodies |
| US6107059A (en) | 1992-04-29 | 2000-08-22 | Affymax Technologies N.V. | Peptide library and screening method |
| EP1550729B1 (en) | 1992-09-25 | 2009-05-27 | Avipep Pty Limited | Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain |
| US5834247A (en) | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
| US5679548A (en) | 1993-02-02 | 1997-10-21 | The Scripps Research Institute | Methods for producing polypeptide metal binding sites and compositions thereof |
| WO1994018221A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| GB9322156D0 (en) | 1993-10-27 | 1993-12-15 | Univ Newcastel Upon Tyne | Activation of molecules |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| US5468785A (en) | 1994-04-15 | 1995-11-21 | University Of Akron | Cobaloxime photoinitiated free radical polymerizations |
| ES2297832T3 (es) | 1994-08-19 | 2008-05-01 | La Region Wallonne | Conjugados que comprenden un agente antitumoral y su utilizacion. |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP4212111B2 (ja) | 1995-05-03 | 2009-01-21 | バイオエンハンスメンツ リミテッド | 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体 |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| WO1997029131A1 (en) | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US5866341A (en) | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ATE293640T1 (de) | 1997-04-07 | 2005-05-15 | Genentech Inc | Anti-vegf antikörper |
| US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
| US6323322B1 (en) | 1997-04-30 | 2001-11-27 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998052966A1 (en) | 1997-05-19 | 1998-11-26 | The Johns Hopkins University School Of Medecine | Tissue specific prodrug |
| US6326162B1 (en) | 1997-07-25 | 2001-12-04 | Bristol-Myers Squibb Pharma Company | Assays and peptide substrate for determining aggrecan degrading metallo protease activity |
| US20030032103A1 (en) | 1997-09-18 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| WO2000004192A1 (en) | 1998-07-17 | 2000-01-27 | Emory University | Methods for detecting and mapping genes, mutations and variant polynucleotide sequences |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US6203989B1 (en) | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
| US6180343B1 (en) | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
| CZ300762B6 (cs) * | 1998-10-16 | 2009-08-05 | Biogen Idec Ma Inc. | Fúzní proteiny interferonu-beta-1a a jejich použití |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US6534061B1 (en) | 1999-04-12 | 2003-03-18 | Genentech, Inc. | Tumor necrosis factor receptor homologs and nucleic acids encoding the same |
| IL129427A0 (en) * | 1999-04-13 | 2000-02-17 | Yeda Res & Dev | Preparation of biologically active molecules |
| CN1308347C (zh) * | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
| US6903196B1 (en) | 1999-06-17 | 2005-06-07 | Utah Ventures Ii, L.P. | Methods for identifying and isolating tissue-specific lumen-exposed molecules |
| US20040146516A1 (en) | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
| EP1204682B1 (en) | 1999-07-28 | 2010-11-17 | Genentech, Inc. | Compositions and methods for the treatment of tumors |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| US20050208558A1 (en) | 1999-10-19 | 2005-09-22 | Applera Corporation | Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof |
| DE19952956A1 (de) | 1999-11-03 | 2001-05-17 | Acgt Progenomics Ag | Verfahren zur Verbindung von molekularen Substanzen |
| US6548248B1 (en) * | 1999-11-10 | 2003-04-15 | Propper Manufacturing Co., Inc. | DNA sterilization indicator |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2001254857A1 (en) | 2000-04-11 | 2001-10-23 | Institut Pasteur | Listeria monocytogenes genome, polypeptides and uses |
| US7514067B2 (en) | 2000-04-25 | 2009-04-07 | President And Fellows Of Harvard College | Methods for tumor diagnosis and therapy |
| US20040181830A1 (en) * | 2001-05-07 | 2004-09-16 | Kovalic David K. | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| EP1286700A2 (en) * | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| JP2003534387A (ja) * | 2000-06-01 | 2003-11-18 | ユニべルシテ・カトリック・ドゥ・ルベン | 腫瘍活性化プロドラッグ化合物、並びにこれらの製造方法及び使用方法 |
| US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| US6625945B2 (en) | 2000-08-08 | 2003-09-30 | Alfred D. Commins | Balanced, multi-stud hold-down |
| DE10045592A1 (de) | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| EP1324771B2 (en) | 2000-10-09 | 2018-06-06 | CytomX Therapeutics, Inc. | Therapeutic and tolerance inducing antibodies |
| CA2432489A1 (en) | 2001-01-04 | 2002-08-29 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Detection of protein conformation using a split ubiquitin reporter system |
| US7141392B2 (en) | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| EP1355675A1 (en) | 2001-01-30 | 2003-10-29 | Universite Catholique De Louvain | Anti-tumor compounds |
| KR20030074839A (ko) | 2001-02-19 | 2003-09-19 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질 항-ｅｇｆｒ 항체 |
| HUP0303171A2 (hu) | 2001-02-19 | 2003-12-29 | Merck Patent Gmbh | Csökkentett immunogenitású mesterséges fehérjék |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| WO2003011317A1 (en) * | 2001-07-25 | 2003-02-13 | Lorantis Limited | Modulators of notch signalling for use in immunotherapy |
| GB0118155D0 (en) | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| DE60235761D1 (de) | 2001-08-01 | 2010-05-06 | Univ Bristol Clifton | Isoform des vegfs |
| US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030134824A1 (en) | 2001-11-12 | 2003-07-17 | Ronald Breslow | Beta-cyclodextrin dimers and phthalocyanines and uses thereof |
| AU2002366303B2 (en) | 2001-12-17 | 2007-09-20 | University College Cardiff Consultants Limited | Enzymatic cleavable reagents for specific delivery to disease sites |
| CA2475388A1 (en) | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
| WO2003086459A1 (en) | 2002-04-12 | 2003-10-23 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| JP4351430B2 (ja) | 2002-10-04 | 2009-10-28 | 財団法人癌研究会 | ナノ黒鉛構造体に結合能を有するペプチド |
| AU2003288467A1 (en) | 2002-12-13 | 2004-07-09 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
| CA2536357A1 (en) | 2003-05-29 | 2004-12-23 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| US20050009110A1 (en) | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
| CA2534055A1 (en) | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody cdr polypeptide sequences with restricted diversity |
| DE602004023956D1 (de) | 2003-08-18 | 2009-12-17 | Univ California | Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon |
| US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| US7431915B2 (en) | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| WO2005051315A2 (en) | 2003-11-24 | 2005-06-09 | The Regents Of The University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| WO2005067980A2 (en) | 2004-01-12 | 2005-07-28 | Pointilliste, Inc. | Design of therapeutics and therapeutics |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| GB0404187D0 (en) | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
| EP1579873A1 (en) | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
| US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
| WO2006090813A1 (ja) | 2005-02-25 | 2006-08-31 | National University Corporation Hokkaido University | 腫瘍組織で選択的に分解性を示す血中滞留性素子 |
| WO2006108052A2 (en) | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
| DE102005036542A1 (de) | 2005-08-03 | 2007-02-08 | Universität Stuttgart | CTL-Prodrug |
| CA2620886C (en) | 2005-08-31 | 2017-03-14 | The Regents Of The University Of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| US20090130776A1 (en) | 2005-09-01 | 2009-05-21 | Canon Kabushiki Kaisha | Binding protein molecule |
| JP4567563B2 (ja) | 2005-09-22 | 2010-10-20 | 富士通株式会社 | 携帯端末装置、ヒンジ装置、筒状部材及び光通信システム |
| EP1770099A1 (en) | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| EP1966242A1 (en) | 2005-12-06 | 2008-09-10 | Domantis Limited | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| GB0604187D0 (en) | 2006-03-02 | 2006-04-12 | Fusion Antibodies Ltd | Peptide and uses thereof |
| US20090246142A1 (en) | 2006-03-10 | 2009-10-01 | Massachusetts Institute Of Technology | Triggered Self-Assembly of Nanoparticles In Vivo |
| JP2009529522A (ja) | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| MX2008011874A (es) | 2006-03-17 | 2009-01-07 | Biogen Idec Inc | Composiciones estabilizadas de polipeptidos. |
| JP4959226B2 (ja) * | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| US8338482B2 (en) * | 2006-07-20 | 2012-12-25 | Wisconsin Alumni Research Foundation | Modulating notch1 signaling pathway for treating neuroendocrine tumors |
| WO2008048680A2 (en) * | 2006-10-19 | 2008-04-24 | Maine Medical Center Research Institute | Notch 2 signaling as a breast cancer suppressor pathway |
| ATE542830T1 (de) * | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| WO2009018500A1 (en) | 2007-07-31 | 2009-02-05 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| MX2010003099A (es) | 2007-09-21 | 2010-05-17 | Univ California | Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales. |
| EA201500156A3 (ru) | 2008-01-03 | 2017-09-29 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
| US20100189727A1 (en) | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| CA2749339A1 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| CN102481341B (zh) | 2009-02-23 | 2017-05-17 | 希托马克斯医疗有限公司 | 蛋白原及其使用方法 |
| US11136353B2 (en) * | 2019-04-15 | 2021-10-05 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof |
-
2010
- 2010-02-23 CN CN201080017140.XA patent/CN102481341B/zh not_active Expired - Fee Related
- 2010-02-23 WO PCT/US2010/025121 patent/WO2010096838A2/en not_active Ceased
- 2010-02-23 US US12/711,199 patent/US8399219B2/en not_active Expired - Fee Related
- 2010-02-23 BR BRPI1011384A patent/BRPI1011384A2/pt active Search and Examination
- 2010-02-23 CA CA2753294A patent/CA2753294A1/en not_active Abandoned
- 2010-02-23 EP EP10744488.7A patent/EP2398494A4/en not_active Withdrawn
- 2010-02-23 RU RU2011138951/10A patent/RU2011138951A/ru not_active Application Discontinuation
- 2010-02-23 AU AU2010215761A patent/AU2010215761B2/en not_active Ceased
- 2010-02-23 JP JP2011551304A patent/JP5861223B2/ja active Active
-
2012
- 2012-12-20 US US13/721,528 patent/US8993266B2/en active Active
-
2015
- 2015-03-30 US US14/673,175 patent/US9644016B2/en active Active
- 2015-07-24 JP JP2015146309A patent/JP2015193653A/ja active Pending
-
2017
- 2017-03-10 AU AU2017201682A patent/AU2017201682A1/en not_active Abandoned
- 2017-05-08 US US15/589,464 patent/US10513549B2/en not_active Expired - Fee Related
-
2019
- 2019-11-11 US US16/680,279 patent/US20200308243A1/en not_active Abandoned
-
2022
- 2022-03-21 US US17/699,846 patent/US20230035290A1/en not_active Abandoned
- 2022-12-19 US US18/068,104 patent/US20230183308A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520059A5 (cg-RX-API-DMAC7.html) | ||
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| JP7125453B2 (ja) | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 | |
| CA2304254A1 (en) | Trimerising module | |
| JP2018171063A5 (cg-RX-API-DMAC7.html) | ||
| US10617741B2 (en) | Compositions and methods for oral delivery of therapeutic cargo | |
| JPWO2021189139A5 (cg-RX-API-DMAC7.html) | ||
| US20240207372A1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| CN115175920A (zh) | 加条形码的xten多肽及其组合物以及其制备和使用方法 | |
| JP2024069465A5 (cg-RX-API-DMAC7.html) | ||
| CA3180251A1 (en) | Cytokine conjugates | |
| US20160222089A1 (en) | Compositions comprising the nc2 domain of collagen ix and methods of using same | |
| CN113874393A (zh) | 对hbv包膜蛋白具有特异性的结合分子 | |
| JPWO2022129560A5 (cg-RX-API-DMAC7.html) | ||
| Ekblad et al. | Synthesis and chemoselective intramolecular crosslinking of a HER2‐binding affibody | |
| CN100400664C (zh) | 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法 | |
| JPWO2023239290A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2022150507A5 (cg-RX-API-DMAC7.html) |